nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—ERBB2—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.0254	0.0254	CbGpPWpGaD
Lapatinib—ERBB4—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.025	0.025	CbGpPWpGaD
Lapatinib—ERBB2—PI-3K cascade—FRS2—nasal cavity cancer	0.0229	0.0229	CbGpPWpGaD
Lapatinib—ERBB4—PI-3K cascade—FRS2—nasal cavity cancer	0.0226	0.0226	CbGpPWpGaD
Lapatinib—ERBB2—PI3K/AKT activation—FRS2—nasal cavity cancer	0.0223	0.0223	CbGpPWpGaD
Lapatinib—ERBB2—GAB1 signalosome—FRS2—nasal cavity cancer	0.0222	0.0222	CbGpPWpGaD
Lapatinib—ERBB4—PI3K/AKT activation—FRS2—nasal cavity cancer	0.022	0.022	CbGpPWpGaD
Lapatinib—ERBB4—GAB1 signalosome—FRS2—nasal cavity cancer	0.0218	0.0218	CbGpPWpGaD
Lapatinib—ERBB2—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.0217	0.0217	CbGpPWpGaD
Lapatinib—ERBB4—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.0213	0.0213	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.0171	0.0171	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.0169	0.0169	CbGpPWpGaD
Lapatinib—EGFR—SHP2 signaling—FRS2—nasal cavity cancer	0.0168	0.0168	CbGpPWpGaD
Lapatinib—ERBB2—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.0164	0.0164	CbGpPWpGaD
Lapatinib—ERBB4—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.0161	0.0161	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by ERBB4—FRS2—nasal cavity cancer	0.0161	0.0161	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by ERBB4—FRS2—nasal cavity cancer	0.0159	0.0159	CbGpPWpGaD
Lapatinib—ERBB2—Downstream signal transduction—FRS2—nasal cavity cancer	0.0154	0.0154	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by FGFR—FRS2—nasal cavity cancer	0.0153	0.0153	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by ERBB2—FRS2—nasal cavity cancer	0.0152	0.0152	CbGpPWpGaD
Lapatinib—ERBB2—DAP12 signaling—FRS2—nasal cavity cancer	0.0152	0.0152	CbGpPWpGaD
Lapatinib—ERBB4—Downstream signal transduction—FRS2—nasal cavity cancer	0.0152	0.0152	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by FGFR—FRS2—nasal cavity cancer	0.0151	0.0151	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by ERBB2—FRS2—nasal cavity cancer	0.015	0.015	CbGpPWpGaD
Lapatinib—ERBB2—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.0149	0.0149	CbGpPWpGaD
Lapatinib—ERBB4—DAP12 signaling—FRS2—nasal cavity cancer	0.0149	0.0149	CbGpPWpGaD
Lapatinib—ERBB4—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.0147	0.0147	CbGpPWpGaD
Lapatinib—ERBB2—DAP12 interactions—FRS2—nasal cavity cancer	0.0143	0.0143	CbGpPWpGaD
Lapatinib—ERBB2—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0143	0.0143	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0143	0.0143	CbGpPWpGaD
Lapatinib—TAP1—Adaptive Immune System—FRS2—nasal cavity cancer	0.0142	0.0142	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by EGFR—FRS2—nasal cavity cancer	0.0141	0.0141	CbGpPWpGaD
Lapatinib—ERBB4—DAP12 interactions—FRS2—nasal cavity cancer	0.0141	0.0141	CbGpPWpGaD
Lapatinib—ERBB4—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0141	0.0141	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0141	0.0141	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.014	0.014	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by PDGF—FRS2—nasal cavity cancer	0.014	0.014	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by EGFR—FRS2—nasal cavity cancer	0.0139	0.0139	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.0138	0.0138	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by PDGF—FRS2—nasal cavity cancer	0.0137	0.0137	CbGpPWpGaD
Lapatinib—ERBB2—B Cell Activation—FRS2—nasal cavity cancer	0.0132	0.0132	CbGpPWpGaD
Lapatinib—ERBB4—B Cell Activation—FRS2—nasal cavity cancer	0.013	0.013	CbGpPWpGaD
Lapatinib—ERBB2—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.0126	0.0126	CbGpPWpGaD
Lapatinib—ERBB4—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.0124	0.0124	CbGpPWpGaD
Lapatinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.0123	0.0123	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—CXCL11—nasal cavity cancer	0.0113	0.0113	CbGpPWpGaD
Lapatinib—EGFR—PI-3K cascade—FRS2—nasal cavity cancer	0.0111	0.0111	CbGpPWpGaD
Lapatinib—EGFR—PI3K/AKT activation—FRS2—nasal cavity cancer	0.0108	0.0108	CbGpPWpGaD
Lapatinib—EGFR—GAB1 signalosome—FRS2—nasal cavity cancer	0.0107	0.0107	CbGpPWpGaD
Lapatinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.0105	0.0105	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by NGF—FRS2—nasal cavity cancer	0.00972	0.00972	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by NGF—FRS2—nasal cavity cancer	0.00957	0.00957	CbGpPWpGaD
Lapatinib—TAP1—Immune System—FRS2—nasal cavity cancer	0.00859	0.00859	CbGpPWpGaD
Lapatinib—EGFR—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00827	0.00827	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00792	0.00792	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00779	0.00779	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—FRS2—nasal cavity cancer	0.00744	0.00744	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—FRS2—nasal cavity cancer	0.0074	0.0074	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00737	0.00737	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—FRS2—nasal cavity cancer	0.00733	0.00733	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00723	0.00723	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—FRS2—nasal cavity cancer	0.0069	0.0069	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0069	0.0069	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0069	0.0069	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—FRS2—nasal cavity cancer	0.00684	0.00684	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00678	0.00678	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—FRS2—nasal cavity cancer	0.00675	0.00675	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—FRS2—nasal cavity cancer	0.00638	0.00638	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00611	0.00611	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—FRS2—nasal cavity cancer	0.00554	0.00554	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—FRS2—nasal cavity cancer	0.00546	0.00546	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—FRS2—nasal cavity cancer	0.00532	0.00532	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—FRS2—nasal cavity cancer	0.00524	0.00524	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—FRS2—nasal cavity cancer	0.0047	0.0047	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00354	0.00354	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00349	0.00349	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—FRS2—nasal cavity cancer	0.00323	0.00323	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—FRS2—nasal cavity cancer	0.00318	0.00318	CbGpPWpGaD
Lapatinib—ERBB2—Disease—FRS2—nasal cavity cancer	0.00298	0.00298	CbGpPWpGaD
Lapatinib—ERBB4—Disease—FRS2—nasal cavity cancer	0.00294	0.00294	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0029	0.0029	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—FRS2—nasal cavity cancer	0.00268	0.00268	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—FRS2—nasal cavity cancer	0.00257	0.00257	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—FRS2—nasal cavity cancer	0.00209	0.00209	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—FRS2—nasal cavity cancer	0.00206	0.00206	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CXCL11—nasal cavity cancer	0.00171	0.00171	CbGpPWpGaD
Lapatinib—EGFR—Immune System—FRS2—nasal cavity cancer	0.00156	0.00156	CbGpPWpGaD
Lapatinib—EGFR—Disease—FRS2—nasal cavity cancer	0.00144	0.00144	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—FRS2—nasal cavity cancer	0.00101	0.00101	CbGpPWpGaD
